Circumventing the control of PIM1 expression by the JAK2/STAT5 pathway by expressing exogenous PIM1 renders MPN model cells resistant to ruxolitinib, providing evidence that PIMs could play a role during a JAK2 inhibitor resistant state (Fig. 7 and Supplementary Fig. 7). The gene discussed is JAK2; the disease is myeloproliferative disorder.